Bevantolol (
INN) was a drug candidate for angina and hypertension that acted as both a
beta blocker and a
calcium channel blocker.[1][2] It was
discovered and
developed by
Warner-Lambert[3] but in January 1989 the company announced that it had withdrawn the
New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"[4] As of 2016[update] it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.[5]
References
^Frishman WH, Goldberg RJ, Benfield P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris". Drugs. 35 (1): 1–21.
doi:
10.2165/00003495-198835010-00001.
PMID2894292.